{"ticker": {"uuid": "682780c4-a5bb-45f1-9663-9c7eb11a2960", "symbol": "NKTX", "name": "Nkarta\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOV1oxU28tbUlOZDJkcGd0MjdxUGlNNEFLZ3FSZ2FVMEJBdHVPTDBnR2V1WFhJeFNvS0dkcC1weE9oaHVPUEJ3QTR0SkJJSjFqeTVaVzRXRW1UMHJTSWZSUTRva3pkVm56MVh5dmdITy1CTGJhOVVpVnhhTmEtZ19uMGVRbVpsSW40cTllTmYzLV9DNTUzazItblFfOE1IdUdIWGIyTjd4QTRnRmhuc3RoMUJzbm9JMEdvZXNQRXkxZlNXSGtRV1h1OTNtQ0FEZmFBbWl1ZkExb9IB3AFBVV95cUxPTDdIZnlSQi1VS1Y1TVZXX2d6b0YxNkI1S0FZd0hnXzFySUtWYmQ2UkpycVAwRnJCSENfRXQzZGJhNTlZMDI1UWVMQXFVWFdMeTdiUlplT2xyLTF3REpLYzRucldFQVJtekhXUEdReGt0clN3RmJWdS13UE8xRWRSMzJQUTNHX2VFV24tY0NpbWVUSUhRTmJFcm05YWkyMElPeDV4VHhGSDdBcGpDVWdLX2pXc29tMDJxODZGSEVwd2drQzVIdFg4MGE2cTA1ellDSDNfQ2F4WklxQ3lX?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T10:19:15+00:00", "published_display": "07 Jul 2026 10:19", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11", "summary": "Needham has reiterated its Buy rating for Nkarta (NKTX.US), maintaining a target price of $11. This indicates the firm's continued confidence in the company's prospects.", "url": "https://www.moomoo.com/news/post/69921659/needham-maintains-nkarta-nktxus-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-07-02T05:10:11", "published_display": "02 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta at H.C. Wainwright cell therapy conference: autoimmune push By Investing.com", "summary": "Nkarta (NKTX) presented its allogeneic CAR NK platform for autoimmune diseases at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. The company is focusing on B-cell-driven autoimmune diseases like lupus nephritis and rheumatoid arthritis, aiming for outpatient trea", "url": "https://uk.investing.com/news/transcripts/nkarta-at-hc-wainwright-cell-therapy-conference-autoimmune-push-93CH-4751220", "source_name": "Investing.com UK", "published_at": "2026-06-30T18:40:33", "published_display": "30 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference", "summary": "Nkarta, Inc. announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. President Nadir Mahmood will present updates on the company's investigational CAR-NK cell therapy for autoimmune diseases in a fireside chat on June 30th at 2 p.m. ET. A we", "url": "https://finance.yahoo.com/healthcare/articles/nkarta-participate-h-c-wainwright-124500628.html", "source_name": "Market source", "published_at": "2026-06-30T08:12:35", "published_display": "30 Jun 2026 08:12", "sentiment": "positive", "sentiment_pct": 61, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Nkarta, Inc. \u2013 NASDAQ:NKTX", "summary": "This page displays the forward \"Price to sales\" metric for Nkarta, Inc. (NASDAQ: NKTX). The content is primarily a data placeholder, indicating the period, value, and change for this financial metric, but the actual numerical data is not provided in the extracted content.", "url": "https://www.tradingview.com/symbols/NASDAQ-NKTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T06:10:48", "published_display": "30 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Nkarta, Inc. \u2013 NASDAQ:NKTX", "summary": "The article \"Price to book forward of Nkarta, Inc. \u2013 NASDAQ:NKTX\" provides a snapshot of Nkarta, Inc.'s stock (NKTX) on the Nasdaq. It shows the company's financial data, specifically focusing on its price to book forward metric. The brief content indicates that the market was cl", "url": "https://www.tradingview.com/symbols/NASDAQ-NKTX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:10:19", "published_display": "29 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Nkarta, Inc. \u2013 NASDAQ:NKTX", "summary": "This article provides financial information for Nkarta, Inc. (NASDAQ: NKTX), specifically focusing on its enterprise value to revenue forward. It appears to be a financial data page from TradingView, offering an overview of the company's financials, news, and other related market", "url": "https://www.tradingview.com/symbols/NASDAQ-NKTX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:12:49", "published_display": "29 Jun 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta to present CAR-NK cell therapy updates a...", "summary": "Nkarta, Inc., a clinical-stage biotech company, will present updates on its investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. President Nadir Mahmood will discuss the pro", "url": "https://pluang.com/en/news-feed/nkarta-ikut-konferensi-terapi-sel-virtual-hc-wainwright", "source_name": "Pluang", "published_at": "2026-06-28T07:40:06", "published_display": "28 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta sets June 30 fireside chat on CAR-NK autoimmune therapy", "summary": "Nkarta (Nasdaq: NKTX), a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. President Nadir Mahmood will host a fireside chat at 2 p.m. ET to discuss the company\u2019s investigational CAR-NK c", "url": "https://www.stocktitan.net/news/NKTX/nkarta-to-participate-in-h-c-wainwright-4th-annual-cell-therapy-p2fxmrqachjc.html", "source_name": "Stock Titan", "published_at": "2026-06-26T12:39:40", "published_display": "26 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Initiates Nkarta(NKTX.US) With Buy Rating", "summary": "TD Cowen has initiated coverage on Nkarta (NKTX.US) with a Buy rating. The firm has set a price target of $10.00 for the biopharmaceutical company.", "url": "https://www.moomoo.com/news/post/71892068/td-cowen-initiates-nkarta-nktxus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-06-24T02:40:27", "published_display": "24 Jun 2026 02:40", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen initiates Nkarta stock with buy rating on NK cell therapy", "summary": "TD Cowen has initiated coverage on Nkarta Inc. (NASDAQ:NKTX) with a \"buy\" rating, citing the potential of its lead candidate NKX019, an engineered natural killer cell therapy, to advance the standard of care in autoimmune diseases. The stock has seen a 60% surge over the past yea", "url": "https://www.investing.com/news/analyst-ratings/td-cowen-initiates-nkarta-stock-with-buy-rating-on-nk-cell-therapy-93CH-4755013", "source_name": "Investing.com", "published_at": "2026-06-23T11:09:53", "published_display": "23 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Initiates Nkarta at Buy", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/td-cowen-initiates-nkarta-buy-100558363.html", "source_name": "MT Newswires", "published_at": "2026-06-23T10:05:58+00:00", "published_display": "23 Jun 2026 10:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shares of Nkarta (NKTX) CEO Paul J. Hastings decrease by 1,776. He still owns 390,247 shares.", "summary": "Nkarta, Inc. CEO Paul J. Hastings reported a sale of 1,776 common stock shares at $2.71 each, primarily to cover tax withholding obligations related to Restricted Stock Unit vesting. This transaction is considered routine and non-discretionary, as indicated in the filing. Followi", "url": "https://www.stocktitan.net/sec-filings/NKTX/form-4-nkarta-inc-insider-trading-activity-6310e34a8394.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:41:00", "published_display": "22 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta (NKTX) Stock Price, News & Analysis", "summary": "Nkarta, Inc. (NASDAQ: NKTX) is a clinical-stage biotechnology company developing off-the-shelf natural killer (NK) cell therapies for cancer. The stock currently trades at $2.79, with analysts giving it a \"Moderate Buy\" consensus rating and a price target of $10.75, representing ", "url": "https://www.marketbeat.com/stocks/NASDAQ/NKTX/", "source_name": "MarketBeat", "published_at": "2026-06-20T12:09:53", "published_display": "20 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Inc (NKTX) Institutional Confidence", "summary": "Nkarta Inc (NKTX) has an institutional shareholding score of 7.00, placing it 81st out of 389 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 82.11%, which is a 4.32% decrease quarter-over-quarter. James Simons is the largest ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nktx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T23:10:55", "published_display": "18 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Inc (NKTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Nkarta Inc (NKTX), highlighting its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. The stock is currently ranked 144 out of 389 in the Biotechnology & Medical ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nktx/technical", "source_name": "TradingKey", "published_at": "2026-06-18T10:40:42", "published_display": "18 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Inc (NKTX) Valuation: PE, PB & Fair Value Analysis", "summary": "Nkarta Inc (NKTX) currently has a valuation score of 8.53, placing it 115th out of 389 companies in the Biotechnology & Medical Research industry. The company's current P/E ratio is -2.12, which is significantly below its recent high and above its recent low. However, relevant da", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nktx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:40:42", "published_display": "18 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Inc (NKTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a brief overview of Nkarta Inc.'s (NKTX) revenue breakdown. It states that relevant data for business segments and regional revenue and profit contribution for fiscal years 2018, 2019, and 2020 have not yet been disclosed by the company. The only specific da", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nktx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T23:09:07", "published_display": "17 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Inc (NKTX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of Nkarta Inc's (NKTX) financial health, ranking it 355 out of 388 in the Biotechnology & Medical Research industry with a weak financial status and low operating efficiency. The report details the company's scores across various financial dimens", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nktx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T22:09:58", "published_display": "17 Jun 2026 22:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Inc (NKTX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Nkarta Inc (NKTX), listing its major shareholders and their respective proportions as of recent updates. It breaks down shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nktx/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T19:41:36", "published_display": "17 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Inc (NKTX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article from TradingKey provides a dividend and stock split history for Nkarta Inc (NKTX). It indicates that Nkarta Inc has not distributed any dividends over the past five years and shows no record of stock splits. The report emphasizes the absence of both dividend and stoc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nktx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T19:41:36", "published_display": "17 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Inc (NKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Nkarta Inc (NKTX) has an earnings forecast score of 9.00, placing it 14th out of 388 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $11.00 for NKTX, with a \"Strong Buy\" rating from 4 analysts, indicating a significant upside potenti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nktx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T09:41:36", "published_display": "17 Jun 2026 09:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay", "summary": "Nkarta (NKTX) shareholders recently re-elected directors Ali Behbahani and Zachary Scheiner, ratified Ernst & Young LLP as their independent auditor, and approved executive compensation. They also expressed a preference for annual say-on-pay votes, which the board has adopted. Ti", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NKTX/pressreleases/2449114/nkarta-shareholders-back-directors-auditor-and-annual-say-on-pay/", "source_name": "The Globe and Mail", "published_at": "2026-06-15T23:41:00", "published_display": "15 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta (NASDAQ: NKTX) reports 37,000-share option grant tied to RA Capital", "summary": "Nkarta, Inc. (NASDAQ: NKTX) has reported a Form 4 detailing a compensation-related stock option grant of 37,000 shares of common stock at an exercise price of $2.46. This grant is tied to RA Capital-affiliated entities, with Dr. Scheiner holding the option for the benefit of RA C", "url": "https://www.stocktitan.net/sec-filings/NKTX/form-4-nkarta-inc-insider-trading-activity-1b9072898f31.html", "source_name": "Stock Titan", "published_at": "2026-06-12T10:09:07", "published_display": "12 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta (NKTX) investors approve directors, auditor and annual say-on-pay", "summary": "Nkarta, Inc. held its 2026 annual meeting where shareholders elected two Class III directors, Ali Behbahani and Zachary Scheiner, and ratified Ernst & Young LLP as the independent auditor for the year ending December 31, 2026. Stockholders also approved, on an advisory basis, the", "url": "https://www.stocktitan.net/sec-filings/NKTX/8-k-nkarta-inc-reports-material-event-13b9d9861760.html", "source_name": "Stock Titan", "published_at": "2026-06-11T21:11:01", "published_display": "11 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta (NKTX) director receives stock options on 37,000 common shares", "summary": "Nkarta, Inc. director George Vratsanos was granted stock options for 37,000 shares of common stock at an exercise price of $2.46 per share. This compensation-related award vests 100% on the earlier of June 10, 2027, or the day before the first annual stockholder meeting following", "url": "https://www.stocktitan.net/sec-filings/NKTX/form-4-nkarta-inc-insider-trading-activity-f8f69d583496.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:11:01", "published_display": "11 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta (NKTX) director George Simeon awarded 37,000-share stock option grant", "summary": "Nkarta, Inc. director George Simeon was granted a stock option for 37,000 shares of common stock with an exercise price of $2.4600 per share, expiring on June 9, 2036. The option vests 100% on the earlier of June 10, 2027, or the day before the first annual stockholders' meeting ", "url": "https://www.stocktitan.net/sec-filings/NKTX/form-4-nkarta-inc-insider-trading-activity-d25b467add7f.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:11:00", "published_display": "11 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta (NKTX) director awarded 37,000 stock options vesting in 2027", "summary": "Nkarta, Inc. director Ali Behbahani has been granted 37,000 stock options with an exercise price of $2.46 per share and an expiration date of June 9, 2036. These options are set to fully vest on the earlier of June 10, 2027, or the day before the first annual stockholder meeting ", "url": "https://www.stocktitan.net/sec-filings/NKTX/form-4-nkarta-inc-insider-trading-activity-6828fbb15dea.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:11:00", "published_display": "11 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta (NKTX) director granted 37,000 stock options for RA Capital funds", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNYlREdVpXcF95VFlKLWxCSmRDLUFqLTA1OG9tWmZsNFc1emJrY190X2lvdVpDb1g0cHJpV0g4TTQ3MG9rNXFJYnI5emFMcFY4NFJzSEhjb2ZwekpfNGQ4bzdPNndFaXpTLTVoLXVqRGE0b1dZd2c0NDQ0WlRLcTdZNlJiUXVrdUVlcGZ0NnFWWWRVQVRRdm1pMzJLY2lvVGNHeWZTNmJuMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta director granted options on 37,000 shares | NKTX Insider Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNT08xYnRKTnY2ZXJnaEJGUVpwcGRJaGgwS25BaC1qTmk4eTFWUWNkenVaVi1zR3hMY1RoZVZaUDVhWEpZS2FRTlZIeExkOWZEWkFWenJSOG9IcHZjMTdnZDFLTjdFdjVqZDZGMXNWWHhkbi1rRlZlSjhWa190TFZRLU5MSlFOLWMxMVFDclVDOVVuMkplZURBaE80dGRreU1YWmk3SFJJTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NKTX - Nkarta Inc Stock Price and Quote", "summary": "This article provides comprehensive financial data and news for Nkarta Inc (NKTX), a biopharmaceutical company focused on natural killer cell therapies. It details stock performance, key financial metrics, insider transactions, and a history of analyst ratings. Recent news highli", "url": "https://finviz.com/stock?t=NKTX", "source_name": "Finviz", "published_at": "2026-06-05T17:39:33", "published_display": "05 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPSFRHUXR5MXRrLWYzeHE5Nzk1MlN6c1FHYW5aVWZ4RTJaQUxMd3lTMS10Q1JCUDRibThIUnQyMVR5bUpVNGd2Y1RHTi1IeVI3NU53aEtRR3BvWmNtb1JXamJtZkhDTm5FcHlSVnN4T1dGd0R6UTBKaklTWEI4M0pTS2pOUnFndlFCYlhxRzNCeVM?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights", "summary": "", "url": "https://finance.yahoo.com/news/nkarta-reports-first-quarter-2026-200100182.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:01:00+00:00", "published_display": "12 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Should I buy Nkarta (NKTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9lQkQwZkt2NDNmWk1Ic2VVOFEzdFctbFdEWlhFQUR5aURyN28zdk11SW5McGs1ZDYzUG1Xa1Y0cHhNTXJIUUhZWkxpUVFvdmYzUnU0Y05UaHdDWEtmNkxDT2R0SUEweXlLZ0d4UA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What date does Nkarta's (NKTX) report Earnings - Earnings Calendar & Announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE1RVXNTNDJURXVMZG1UWkZNX0RYbnpOWjBHYjExUUNlaE1MNGVXMzFhWmdPM011RmFFUGg5a21KOFJpQ3hrM19sSUJ1b05tWFJVZVFvc3hkZ21EdWg1cEdsNEtXaHE1ajE3RXpV?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta wins FDA nod for new trial protocol (NKTX:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQc0NSaVhfSkZMTF8zdjBCVkQycGNhX2VNamYtZVkzekFXSVNRbGtRNXp2QnhNcllUU1ctQkIxbk9lN0hJZl93VFlKTTA2RGN1cDFVSEowdzJlWHZVMVA3NkVQdEZEODE3UktvdVFWV3U2am5sakNsYVRHQURweDUxV1NR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOZEF5WFM5M3Q1aTh3N0FDcUpRdjhUT2h6T1huazlCNlZIVm1uRzBabDBKaG9ScXhrbXJySGVwaDFHLUVlbFRWQ0RzVjdZMXdVLXVkUjZQZVVaSUpFVkpLYU1MdWNpQnItZG1lRHdPUS1YelNXTnBwOWZKLXhnUWNJT0ZaTVVOZWdCVVotalIza2ExODdqSVoxT2sxX0tRMm16WThCWk1B?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta CEO Hastings sells $53,915 in NKTX stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQQUZ3WC1DNzF6V0YyX19IWDNtZ1lmZDkzc3ROcUF2V3lFcXlpSzJpZ3llMXpKc05YTVpndkxqeThqYWdWTHBRcGd1X3IyeExxM1l4T0FOdVdRbkd0dWtuTmhFQWw5NG9xaFFKeHJGRk93S19Zb3BfRHExNTBzbjhNYUxqVlZXYTAwRU12MUNtR2xLM2JUbDREaVNQNnBueC1LejdJUEN2TXFnS1FuaFlv?oc=5", "source_name": "Investing.com", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Nkarta (NASDAQ:NKTX) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOTXcyendoZDhFT2Y0bkNVUk04dnlnZ0VsSkptRjVQRnhaR0ZnakI3SUVjNWxiR2wydWZDeFNwWEgtMFJENnd4Z2x6elgxakZQVlNWYmlKcWltcE56RklOd2NlYnV6eWJDd0VPMS11d0dwUTFPcEdQLVk3czJLYkQ3c3F3?oc=5", "source_name": "Market source", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta (NASDAQ: NKTX) presenting ACR 2025 poster on NKX019, including B-cell depletion data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNdW9PN0t1QldUbVlqbnQ3ZkJIOUF1ODV0WW9CU1k2dTlFWFY4dm05akNlMVRkSTZWQUhWUmRUWXlnOUxJNGJzWlMzNVc1aXpQRVlYSHU5TmptMmpyd1hFM05jVEVVaGNwRjhLR2E5M0R5ZUsyQmRRNXFISkJWNlJSMjdneC0tTTdSOWszOHROWFlGS2JqSGlzWlBzdEt1X0JFRXpleXQ1S0VxSHN2aUUtRnA0c0RVcDIyVTQ3Ty1MWU8?oc=5", "source_name": "Stock Titan", "published_at": "2025-10-22T07:00:00+00:00", "published_display": "22 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NKarta chief Paul Hastings discusses thriving in biotech amid political turmoil", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNY3MxSGt4T0VFY0QwN3llM1E5YkMzUmhNeXR1a09fT0Y3Yl81S1pzbUNlUldURXVJMmdCNUFzUklMSzFycDljQUxYVlNVYmswbnNqSnVMTExzbi1SdXFVM2p4bXJod2d4QjFSb3JzakVtYkl4djVLOEhNeVVjWDB6N0ZLWEE1YzRDWUpkMEEwcGduV2JsRTJ3SnhLaGtjMDFjQWFqalJpRXYxSzJicVFDWVNNMUNLQ2dkWl9OZQ?oc=5", "source_name": "BioProcess International", "published_at": "2025-07-15T07:00:00+00:00", "published_display": "15 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T10:19:15+00:00", "published_display": "07 Jul 2026 10:19", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11", "summary": "Needham has reiterated its Buy rating for Nkarta (NKTX.US), maintaining a target price of $11. This indicates the firm's continued confidence in the company's prospects.", "url": "https://www.moomoo.com/news/post/69921659/needham-maintains-nkarta-nktxus-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-07-02T05:10:11", "published_display": "02 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta at H.C. Wainwright cell therapy conference: autoimmune push By Investing.com", "summary": "Nkarta (NKTX) presented its allogeneic CAR NK platform for autoimmune diseases at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. The company is focusing on B-cell-driven autoimmune diseases like lupus nephritis and rheumatoid arthritis, aiming for outpatient trea", "url": "https://uk.investing.com/news/transcripts/nkarta-at-hc-wainwright-cell-therapy-conference-autoimmune-push-93CH-4751220", "source_name": "Investing.com UK", "published_at": "2026-06-30T18:40:33", "published_display": "30 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference", "summary": "Nkarta, Inc. announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. President Nadir Mahmood will present updates on the company's investigational CAR-NK cell therapy for autoimmune diseases in a fireside chat on June 30th at 2 p.m. ET. A we", "url": "https://finance.yahoo.com/healthcare/articles/nkarta-participate-h-c-wainwright-124500628.html", "source_name": "Market source", "published_at": "2026-06-30T08:12:35", "published_display": "30 Jun 2026 08:12", "sentiment": "positive", "sentiment_pct": 61, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Nkarta, Inc. \u2013 NASDAQ:NKTX", "summary": "This page displays the forward \"Price to sales\" metric for Nkarta, Inc. (NASDAQ: NKTX). The content is primarily a data placeholder, indicating the period, value, and change for this financial metric, but the actual numerical data is not provided in the extracted content.", "url": "https://www.tradingview.com/symbols/NASDAQ-NKTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T06:10:48", "published_display": "30 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Nkarta, Inc. \u2013 NASDAQ:NKTX", "summary": "The article \"Price to book forward of Nkarta, Inc. \u2013 NASDAQ:NKTX\" provides a snapshot of Nkarta, Inc.'s stock (NKTX) on the Nasdaq. It shows the company's financial data, specifically focusing on its price to book forward metric. The brief content indicates that the market was cl", "url": "https://www.tradingview.com/symbols/NASDAQ-NKTX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:10:19", "published_display": "29 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Nkarta, Inc. \u2013 NASDAQ:NKTX", "summary": "This article provides financial information for Nkarta, Inc. (NASDAQ: NKTX), specifically focusing on its enterprise value to revenue forward. It appears to be a financial data page from TradingView, offering an overview of the company's financials, news, and other related market", "url": "https://www.tradingview.com/symbols/NASDAQ-NKTX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:12:49", "published_display": "29 Jun 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta to present CAR-NK cell therapy updates a...", "summary": "Nkarta, Inc., a clinical-stage biotech company, will present updates on its investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. President Nadir Mahmood will discuss the pro", "url": "https://pluang.com/en/news-feed/nkarta-ikut-konferensi-terapi-sel-virtual-hc-wainwright", "source_name": "Pluang", "published_at": "2026-06-28T07:40:06", "published_display": "28 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta sets June 30 fireside chat on CAR-NK autoimmune therapy", "summary": "Nkarta (Nasdaq: NKTX), a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. President Nadir Mahmood will host a fireside chat at 2 p.m. ET to discuss the company\u2019s investigational CAR-NK c", "url": "https://www.stocktitan.net/news/NKTX/nkarta-to-participate-in-h-c-wainwright-4th-annual-cell-therapy-p2fxmrqachjc.html", "source_name": "Stock Titan", "published_at": "2026-06-26T12:39:40", "published_display": "26 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Initiates Nkarta(NKTX.US) With Buy Rating", "summary": "TD Cowen has initiated coverage on Nkarta (NKTX.US) with a Buy rating. The firm has set a price target of $10.00 for the biopharmaceutical company.", "url": "https://www.moomoo.com/news/post/71892068/td-cowen-initiates-nkarta-nktxus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-06-24T02:40:27", "published_display": "24 Jun 2026 02:40", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen initiates Nkarta stock with buy rating on NK cell therapy", "summary": "TD Cowen has initiated coverage on Nkarta Inc. (NASDAQ:NKTX) with a \"buy\" rating, citing the potential of its lead candidate NKX019, an engineered natural killer cell therapy, to advance the standard of care in autoimmune diseases. The stock has seen a 60% surge over the past yea", "url": "https://www.investing.com/news/analyst-ratings/td-cowen-initiates-nkarta-stock-with-buy-rating-on-nk-cell-therapy-93CH-4755013", "source_name": "Investing.com", "published_at": "2026-06-23T11:09:53", "published_display": "23 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Initiates Nkarta at Buy", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/td-cowen-initiates-nkarta-buy-100558363.html", "source_name": "MT Newswires", "published_at": "2026-06-23T10:05:58+00:00", "published_display": "23 Jun 2026 10:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shares of Nkarta (NKTX) CEO Paul J. Hastings decrease by 1,776. He still owns 390,247 shares.", "summary": "Nkarta, Inc. CEO Paul J. Hastings reported a sale of 1,776 common stock shares at $2.71 each, primarily to cover tax withholding obligations related to Restricted Stock Unit vesting. This transaction is considered routine and non-discretionary, as indicated in the filing. Followi", "url": "https://www.stocktitan.net/sec-filings/NKTX/form-4-nkarta-inc-insider-trading-activity-6310e34a8394.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:41:00", "published_display": "22 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta (NKTX) Stock Price, News & Analysis", "summary": "Nkarta, Inc. (NASDAQ: NKTX) is a clinical-stage biotechnology company developing off-the-shelf natural killer (NK) cell therapies for cancer. The stock currently trades at $2.79, with analysts giving it a \"Moderate Buy\" consensus rating and a price target of $10.75, representing ", "url": "https://www.marketbeat.com/stocks/NASDAQ/NKTX/", "source_name": "MarketBeat", "published_at": "2026-06-20T12:09:53", "published_display": "20 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Inc (NKTX) Institutional Confidence", "summary": "Nkarta Inc (NKTX) has an institutional shareholding score of 7.00, placing it 81st out of 389 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 82.11%, which is a 4.32% decrease quarter-over-quarter. James Simons is the largest ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nktx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T23:10:55", "published_display": "18 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Inc (NKTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Nkarta Inc (NKTX), highlighting its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. The stock is currently ranked 144 out of 389 in the Biotechnology & Medical ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nktx/technical", "source_name": "TradingKey", "published_at": "2026-06-18T10:40:42", "published_display": "18 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Inc (NKTX) Valuation: PE, PB & Fair Value Analysis", "summary": "Nkarta Inc (NKTX) currently has a valuation score of 8.53, placing it 115th out of 389 companies in the Biotechnology & Medical Research industry. The company's current P/E ratio is -2.12, which is significantly below its recent high and above its recent low. However, relevant da", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nktx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:40:42", "published_display": "18 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Inc (NKTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a brief overview of Nkarta Inc.'s (NKTX) revenue breakdown. It states that relevant data for business segments and regional revenue and profit contribution for fiscal years 2018, 2019, and 2020 have not yet been disclosed by the company. The only specific da", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nktx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T23:09:07", "published_display": "17 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Inc (NKTX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of Nkarta Inc's (NKTX) financial health, ranking it 355 out of 388 in the Biotechnology & Medical Research industry with a weak financial status and low operating efficiency. The report details the company's scores across various financial dimens", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nktx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T22:09:58", "published_display": "17 Jun 2026 22:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Inc (NKTX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Nkarta Inc (NKTX), listing its major shareholders and their respective proportions as of recent updates. It breaks down shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nktx/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T19:41:36", "published_display": "17 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Inc (NKTX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article from TradingKey provides a dividend and stock split history for Nkarta Inc (NKTX). It indicates that Nkarta Inc has not distributed any dividends over the past five years and shows no record of stock splits. The report emphasizes the absence of both dividend and stoc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nktx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T19:41:36", "published_display": "17 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Inc (NKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Nkarta Inc (NKTX) has an earnings forecast score of 9.00, placing it 14th out of 388 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $11.00 for NKTX, with a \"Strong Buy\" rating from 4 analysts, indicating a significant upside potenti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nktx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T09:41:36", "published_display": "17 Jun 2026 09:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay", "summary": "Nkarta (NKTX) shareholders recently re-elected directors Ali Behbahani and Zachary Scheiner, ratified Ernst & Young LLP as their independent auditor, and approved executive compensation. They also expressed a preference for annual say-on-pay votes, which the board has adopted. Ti", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NKTX/pressreleases/2449114/nkarta-shareholders-back-directors-auditor-and-annual-say-on-pay/", "source_name": "The Globe and Mail", "published_at": "2026-06-15T23:41:00", "published_display": "15 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta (NASDAQ: NKTX) reports 37,000-share option grant tied to RA Capital", "summary": "Nkarta, Inc. (NASDAQ: NKTX) has reported a Form 4 detailing a compensation-related stock option grant of 37,000 shares of common stock at an exercise price of $2.46. This grant is tied to RA Capital-affiliated entities, with Dr. Scheiner holding the option for the benefit of RA C", "url": "https://www.stocktitan.net/sec-filings/NKTX/form-4-nkarta-inc-insider-trading-activity-1b9072898f31.html", "source_name": "Stock Titan", "published_at": "2026-06-12T10:09:07", "published_display": "12 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta (NKTX) investors approve directors, auditor and annual say-on-pay", "summary": "Nkarta, Inc. held its 2026 annual meeting where shareholders elected two Class III directors, Ali Behbahani and Zachary Scheiner, and ratified Ernst & Young LLP as the independent auditor for the year ending December 31, 2026. Stockholders also approved, on an advisory basis, the", "url": "https://www.stocktitan.net/sec-filings/NKTX/8-k-nkarta-inc-reports-material-event-13b9d9861760.html", "source_name": "Stock Titan", "published_at": "2026-06-11T21:11:01", "published_display": "11 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta (NKTX) director receives stock options on 37,000 common shares", "summary": "Nkarta, Inc. director George Vratsanos was granted stock options for 37,000 shares of common stock at an exercise price of $2.46 per share. This compensation-related award vests 100% on the earlier of June 10, 2027, or the day before the first annual stockholder meeting following", "url": "https://www.stocktitan.net/sec-filings/NKTX/form-4-nkarta-inc-insider-trading-activity-f8f69d583496.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:11:01", "published_display": "11 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta (NKTX) director George Simeon awarded 37,000-share stock option grant", "summary": "Nkarta, Inc. director George Simeon was granted a stock option for 37,000 shares of common stock with an exercise price of $2.4600 per share, expiring on June 9, 2036. The option vests 100% on the earlier of June 10, 2027, or the day before the first annual stockholders' meeting ", "url": "https://www.stocktitan.net/sec-filings/NKTX/form-4-nkarta-inc-insider-trading-activity-d25b467add7f.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:11:00", "published_display": "11 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta (NKTX) director awarded 37,000 stock options vesting in 2027", "summary": "Nkarta, Inc. director Ali Behbahani has been granted 37,000 stock options with an exercise price of $2.46 per share and an expiration date of June 9, 2036. These options are set to fully vest on the earlier of June 10, 2027, or the day before the first annual stockholder meeting ", "url": "https://www.stocktitan.net/sec-filings/NKTX/form-4-nkarta-inc-insider-trading-activity-6828fbb15dea.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:11:00", "published_display": "11 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta (NKTX) director granted 37,000 stock options for RA Capital funds", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNYlREdVpXcF95VFlKLWxCSmRDLUFqLTA1OG9tWmZsNFc1emJrY190X2lvdVpDb1g0cHJpV0g4TTQ3MG9rNXFJYnI5emFMcFY4NFJzSEhjb2ZwekpfNGQ4bzdPNndFaXpTLTVoLXVqRGE0b1dZd2c0NDQ0WlRLcTdZNlJiUXVrdUVlcGZ0NnFWWWRVQVRRdm1pMzJLY2lvVGNHeWZTNmJuMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta director granted options on 37,000 shares | NKTX Insider Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNT08xYnRKTnY2ZXJnaEJGUVpwcGRJaGgwS25BaC1qTmk4eTFWUWNkenVaVi1zR3hMY1RoZVZaUDVhWEpZS2FRTlZIeExkOWZEWkFWenJSOG9IcHZjMTdnZDFLTjdFdjVqZDZGMXNWWHhkbi1rRlZlSjhWa190TFZRLU5MSlFOLWMxMVFDclVDOVVuMkplZURBaE80dGRreU1YWmk3SFJJTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NKTX - Nkarta Inc Stock Price and Quote", "summary": "This article provides comprehensive financial data and news for Nkarta Inc (NKTX), a biopharmaceutical company focused on natural killer cell therapies. It details stock performance, key financial metrics, insider transactions, and a history of analyst ratings. Recent news highli", "url": "https://finviz.com/stock?t=NKTX", "source_name": "Finviz", "published_at": "2026-06-05T17:39:33", "published_display": "05 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPSFRHUXR5MXRrLWYzeHE5Nzk1MlN6c1FHYW5aVWZ4RTJaQUxMd3lTMS10Q1JCUDRibThIUnQyMVR5bUpVNGd2Y1RHTi1IeVI3NU53aEtRR3BvWmNtb1JXamJtZkhDTm5FcHlSVnN4T1dGd0R6UTBKaklTWEI4M0pTS2pOUnFndlFCYlhxRzNCeVM?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights", "summary": "", "url": "https://finance.yahoo.com/news/nkarta-reports-first-quarter-2026-200100182.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:01:00+00:00", "published_display": "12 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Nkarta (NKTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9lQkQwZkt2NDNmWk1Ic2VVOFEzdFctbFdEWlhFQUR5aURyN28zdk11SW5McGs1ZDYzUG1Xa1Y0cHhNTXJIUUhZWkxpUVFvdmYzUnU0Y05UaHdDWEtmNkxDT2R0SUEweXlLZ0d4UA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What date does Nkarta's (NKTX) report Earnings - Earnings Calendar & Announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE1RVXNTNDJURXVMZG1UWkZNX0RYbnpOWjBHYjExUUNlaE1MNGVXMzFhWmdPM011RmFFUGg5a21KOFJpQ3hrM19sSUJ1b05tWFJVZVFvc3hkZ21EdWg1cEdsNEtXaHE1ajE3RXpV?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta wins FDA nod for new trial protocol (NKTX:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQc0NSaVhfSkZMTF8zdjBCVkQycGNhX2VNamYtZVkzekFXSVNRbGtRNXp2QnhNcllUU1ctQkIxbk9lN0hJZl93VFlKTTA2RGN1cDFVSEowdzJlWHZVMVA3NkVQdEZEODE3UktvdVFWV3U2am5sakNsYVRHQURweDUxV1NR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOZEF5WFM5M3Q1aTh3N0FDcUpRdjhUT2h6T1huazlCNlZIVm1uRzBabDBKaG9ScXhrbXJySGVwaDFHLUVlbFRWQ0RzVjdZMXdVLXVkUjZQZVVaSUpFVkpLYU1MdWNpQnItZG1lRHdPUS1YelNXTnBwOWZKLXhnUWNJT0ZaTVVOZWdCVVotalIza2ExODdqSVoxT2sxX0tRMm16WThCWk1B?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta CEO Hastings sells $53,915 in NKTX stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQQUZ3WC1DNzF6V0YyX19IWDNtZ1lmZDkzc3ROcUF2V3lFcXlpSzJpZ3llMXpKc05YTVpndkxqeThqYWdWTHBRcGd1X3IyeExxM1l4T0FOdVdRbkd0dWtuTmhFQWw5NG9xaFFKeHJGRk93S19Zb3BfRHExNTBzbjhNYUxqVlZXYTAwRU12MUNtR2xLM2JUbDREaVNQNnBueC1LejdJUEN2TXFnS1FuaFlv?oc=5", "source_name": "Investing.com", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Nkarta (NASDAQ:NKTX) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOTXcyendoZDhFT2Y0bkNVUk04dnlnZ0VsSkptRjVQRnhaR0ZnakI3SUVjNWxiR2wydWZDeFNwWEgtMFJENnd4Z2x6elgxakZQVlNWYmlKcWltcE56RklOd2NlYnV6eWJDd0VPMS11d0dwUTFPcEdQLVk3czJLYkQ3c3F3?oc=5", "source_name": "Market source", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nkarta (NASDAQ: NKTX) presenting ACR 2025 poster on NKX019, including B-cell depletion data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNdW9PN0t1QldUbVlqbnQ3ZkJIOUF1ODV0WW9CU1k2dTlFWFY4dm05akNlMVRkSTZWQUhWUmRUWXlnOUxJNGJzWlMzNVc1aXpQRVlYSHU5TmptMmpyd1hFM05jVEVVaGNwRjhLR2E5M0R5ZUsyQmRRNXFISkJWNlJSMjdneC0tTTdSOWszOHROWFlGS2JqSGlzWlBzdEt1X0JFRXpleXQ1S0VxSHN2aUUtRnA0c0RVcDIyVTQ3Ty1MWU8?oc=5", "source_name": "Stock Titan", "published_at": "2025-10-22T07:00:00+00:00", "published_display": "22 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NKarta chief Paul Hastings discusses thriving in biotech amid political turmoil", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNY3MxSGt4T0VFY0QwN3llM1E5YkMzUmhNeXR1a09fT0Y3Yl81S1pzbUNlUldURXVJMmdCNUFzUklMSzFycDljQUxYVlNVYmswbnNqSnVMTExzbi1SdXFVM2p4bXJod2d4QjFSb3JzakVtYkl4djVLOEhNeVVjWDB6N0ZLWEE1YzRDWUpkMEEwcGduV2JsRTJ3SnhLaGtjMDFjQWFqalJpRXYxSzJicVFDWVNNMUNLQ2dkWl9OZQ?oc=5", "source_name": "BioProcess International", "published_at": "2025-07-15T07:00:00+00:00", "published_display": "15 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 87, "total_relevant": 50, "sentiment_summary": {"positive": 14, "negative": 3, "neutral": 33, "score": 54, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 15.0, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 6.95, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 2.97, "latest_week": "2026-07-10", "one_week_move": -7.8, "four_week_move": 3.8, "twelve_week_move": -14.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.241355, "market_dynamics_buy_signal": false, "relative_strength": 10.25434, "fair_value_gap": -18.1, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 50.2242, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.8% over one week, +3.8% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 10}, {"label": "Market source", "count": 9}, {"label": "TradingKey", "count": 8}, {"label": "simplywall.st", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "Moomoo", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "Zacks Investment Research", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 5}, {"label": "Regulatory and legal", "count": 3}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-7.8% over one week, +3.8% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth"}], "updated_at": "2026-07-16T00:37:28.871363+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}